johnson & johnson - JNJ

JNJ

Close Chg Chg %
234.42 3.34 1.42%

Closed Market

237.76

+3.34 (1.42%)

Volume: 10.26M

Last Updated:

Feb 5, 2026, 3:59 PM EDT

Company Overview: johnson & johnson - JNJ

JNJ Key Data

Open

$235.50

Day Range

234.99 - 239.58

52 Week Range

142.20 - 239.58

Market Cap

$564.91B

Shares Outstanding

2.41B

Public Float

2.41B

Beta

0.34

Rev. Per Employee

N/A

P/E Ratio

21.25

EPS

$9.01

Yield

219.22%

Dividend

$1.30

EX-DIVIDEND DATE

Feb 24, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

9.60M

 

JNJ Performance

1 Week
 
3.18%
 
1 Month
 
14.72%
 
3 Months
 
25.67%
 
1 Year
 
53.13%
 
5 Years
 
42.58%
 

JNJ Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About johnson & johnson - JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

JNJ At a Glance

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
Phone 1-732-524-0400 Revenue 94.19B
Industry Pharmaceuticals: Major Net Income 26.80B
Sector Health Technology 2025 Sales Growth 6.051%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

JNJ Valuation

P/E Current 21.127
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.819
Price to Sales Ratio 5.355
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

JNJ Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

JNJ Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

JNJ Profitability

Gross Margin 72.785
Operating Margin 27.174
Pretax Margin 34.59
Net Margin 28.456
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

JNJ Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Johnson & Johnson - JNJ

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
95.02B 85.15B 88.82B 94.19B
Sales Growth
+1.34% -10.38% +4.31% +6.05%
Cost of Goods Sold (COGS) incl D&A
30.72B 26.43B 27.86B 25.64B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 6.97B 7.49B 7.34B
Depreciation
- 2.67B 2.99B 2.84B
Amortization of Intangibles
4.30B 4.50B 4.50B 4.62B
COGS Growth
+2.83% -13.96% +5.42% -7.99%
Gross Income
64.30B 58.72B 60.96B 68.56B
Gross Income Growth
+0.65% -8.67% +3.81% +12.47%
Gross Profit Margin
+67.67% +68.96% +68.63% +72.78%
2022 2023 2024 2025 5-year trend
SG&A Expense
39.52B 36.56B 40.13B 38.34B
Research & Development
14.75B 15.05B 17.27B 14.66B
Other SG&A
24.77B 21.51B 22.87B 23.68B
SGA Growth
+0.29% -7.48% +9.78% -4.47%
Other Operating Expense
- - - 4.62B
-
Unusual Expense
5.01B 9.31B 6.24B 309.00M
EBIT after Unusual Expense
19.77B 12.85B 14.58B 25.29B
Non Operating Income/Expense
2.79B 3.39B 3.26B 7.29B
Non-Operating Interest Income
490.00M 1.26B 1.33B 85.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 841.00M 1.18B 1.15B
Interest Expense Growth
- +10.80% +39.95% -2.29%
Gross Interest Expense
- 890.00M 1.25B 1.23B
Interest Capitalized
- 49.00M 70.00M 79.00M
Pretax Income
21.73B 15.06B 16.69B 32.58B
Pretax Income Growth
-4.61% -30.67% +10.79% +95.25%
Pretax Margin
+22.86% +17.69% +18.79% +34.59%
Income Tax
3.78B 1.74B 2.62B 5.78B
Income Tax - Current - Domestic
- 2.38B 2.71B 2.20B
Income Tax - Current - Foreign
- 3.07B 3.09B 2.60B
Income Tax - Deferred - Domestic
- (2.08B) (3.44B) (2.54B)
Income Tax - Deferred - Foreign
- 418.00M (619.00M) 356.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
17.94B 13.33B 14.07B 26.80B
Minority Interest Expense
- - - -
-
Net Income
17.94B 13.33B 14.07B 26.80B
Net Income Growth
-14.07% -25.72% +5.55% +90.56%
Net Margin Growth
+18.88% +15.65% +15.84% +28.46%
Extraordinaries & Discontinued Operations
- - - 843.00M
-
Discontinued Operations
- - - 843.00M
-
Net Income After Extraordinaries
17.94B 14.17B 14.07B 26.80B
Preferred Dividends
- - - -
-
Net Income Available to Common
17.94B 14.17B 14.07B 26.80B
EPS (Basic)
- 6.8342 5.5927 5.8431
EPS (Basic) Growth
- -13.84% -18.17% +4.48%
Basic Shares Outstanding
- 2.63B 2.53B 2.41B
EPS (Diluted)
6.7349 5.5339 5.7899 11.0332
EPS (Diluted) Growth
-13.74% -17.83% +4.63% +90.56%
Diluted Shares Outstanding
2.66B 2.56B 2.43B 2.43B
EBITDA
- 31.75B 29.65B 28.16B
EBITDA Growth
- -0.38% -6.62% -5.01%
EBITDA Margin
- +33.42% +34.82% +31.71%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 236.826
Number of Ratings 28 Current Quarters Estimate 2.685
FY Report Date 03 / 2026 Current Year's Estimate 11.568
Last Quarter’s Earnings 2.46 Median PE on CY Estimate N/A
Year Ago Earnings 10.79 Next Fiscal Year Estimate 12.548
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 16 23 23
Mean Estimate 2.69 2.88 11.57 12.55
High Estimates 2.90 3.00 11.95 13.29
Low Estimate 2.14 2.58 11.43 11.85
Coefficient of Variance 7.49 3.45 1.00 2.60

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 11
OVERWEIGHT 4 4 5
HOLD 10 10 10
UNDERWEIGHT 1 2 1
SELL 1 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Johnson & Johnson - JNJ

Date Name Shares Transaction Value
Mar 21, 2025 Joaquin Duato CEO and Chairman of the Board; Director 275,967 Bona fide gift 0.00
Mar 21, 2025 Joaquin Duato CEO and Chairman of the Board; Director 130,852 Bona fide gift 0.00
Mar 7, 2025 Eugene A. Woods Director 3,014 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Marillyn A. Hewson Director 11,691 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Eugene A. Woods Director 250 Open market or private purchase of non-derivative security Non-derivative transaction at $145.53 per share 36,382.50
Feb 27, 2025 Robert J. Decker VP Corporate Controller 28,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $101.87 per share 2,852,360.00
Feb 27, 2025 Robert J. Decker VP Corporate Controller 21,001 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $165.88 per share 3,483,645.88
Feb 27, 2025 Robert J. Decker VP Corporate Controller N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director 415,205 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Vanessa A. Broadhurst EVP, Global Corp Affairs 25,538 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director 3,469 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director 406,819 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $156.71 per share 63,752,605.49
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director 395,923 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $156.15 per share 61,823,376.45
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director 397,525 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Joaquin Duato CEO and Chairman of the Board; Director 393,843 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $156.71 per share 61,719,136.53
Feb 20, 2025 Kristen Blair Mulholland EVP, Chief HR Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 John C. Reed EVP, Innovative Medicine, R&D 2,698 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 John C. Reed EVP, Innovative Medicine, R&D 15,542 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $156.15 per share 2,426,883.30

Johnson & Johnson in the News